MedPath

Practical combination therapy of Amlodin and angiotensin II Receptor blocker(ARB); safety and efficacy in paTieNts with hypERtension Study (PARTNER Study)

Not Applicable
Conditions
Hypertension
Registration Number
JPRN-UMIN000005888
Lead Sponsor
Dainippon Sumitomo Pharma Co.,Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
6000
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Hypertensive Patients who had already received antihypertensive combination therapy with both Amlodin and ARB,and ARB-amlodipine combination agent, before the enrollment (2)Hypertensive patients who have received amlodipine preparation except Amlodin within 12 weeks of the enrollment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath